Might high-dose aspirin be the Brilinta difference?

A new study backs up a suggestion that high dosages of aspirin may interfere with AstraZeneca's heart drug Brilinta, offering a possible explanation for disappointing results from a trial among patients in North America. The drug is approved in Europe, but awaits the OK from U.S. regulators, partly because of this geographical disparity in results. Story | Report

Suggested Articles

Belén Garijo, currently CEO of Merck Healthcare, will succeed Stefan Oschmann as the German company's chief exec when his tenure ends in April 2021.

More than 60 researchers and bioethicists called on Pfizer to take time to collect more COVID-19 vaccine safety data, Bloomberg reports. 

Leaked details about an ad campaign to quell coronavirus fears before the election raise "every red flag I could dream of," an ex-HHS official said.